L-Sepiapterin
Based on 1 publication(s) in Google Scholar
L-Sepiapterin (Sepiapterin), is a phenylalanine hydroxylase activator, is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. L-Sepiapterin can be used for the study of hyperphenylalaninemia.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 90.48%
- No. CAS: 17094-01-8
- Fòrmula: C9H11N5O3
- Peso molecular:237.22
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) L-Sepiapterin
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
|
Human Endogenous Metabolite |
L-Sepiapterin (Sepiapterin) (0.1-10 μM; 24 hpurs) Iinduces cell proliferation in a dose-dependent manner[1].
L-Sepiapterin (1-50 μM; 20 minutes) significantly inhibits the phosphorylation of VEGF-A-induced (50 ng/ml) p70S6K[1].
L-Sepiapterin inhibits VEGF-A-induced cell proliferation and migration through NO-independent mechanism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SKOV-3 cells
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:24 hours
-
Result:Induced cell proliferation in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/KsJ diabetic mice (db/db)[2]
-
Dosage:10 mg/kg
-
Administration:P.o. (powder chow); daily for or 8 weeks
-
Result:Significantly improved the relaxation to Ach in SMA from db/db mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 17094-01-8
-
Appearance Solid
-
Peso molecular 237.22
-
Fòrmula C9H11N5O3
-
Color White to yellow
-
SMILES
O=C1NC(N)=NC2=C1N=C(C([C@@H](O)C)=O)CN2
-
Synonyms
Sepiapterin
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Targeted endothelial GTPCH1/BH4 pathway activation reverses vascular dysfunction in smoking-associated obesity. [Abstract]2026 Jul:249:117931. PMID: 41895618
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Pannirselvam M, et al. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol. 2003;140(4):701‐706. [Content Brief]
[2]. Cho YR, et al. Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. Oncol Rep. 2011;26(4):861‐867. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
L-Sepiapterin Related Classifications
HY-112234 Related Classifications
Powered by Bioz